A Study of DXC018 in Patients With Advanced Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC018 in participants with Advanced Solid Tumors.
Trial Details
NCT Number NCT07849218
Lead Sponsor Hangzhou DAC Biotechnology Co., Ltd.
Conditions
(from sponsor)		 Advanced Solid Tumors
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov